Meiogenix develops a chromosome-editing platform that accelerates generation of biodiversity by mixing parental genomes during plant reproduction to restore immunity, improve quality and reduce chemical inputs. The company applies gene and chromosome editing to shorten variety selection timelines and address losses in crop biodiversity. Key stated benefits include increased pest and disease resistance, better taste and flavor, and higher yields across major crops. Meiogenix cites collaborations with Cornell and Bayer to develop improved crops and to care for environmental impacts. The company is pursuing international expansion and plans product development focus in North America and implementation in the United States. Meiogenix recently closed a $13 million (€11 million) Series A, targeting the commercial seed market (reported at $50 billion) and a broader market expected to surpass $60 billion by 2025.

Total raised

$12M

Funding rounds

1

Latest round

Series A

Latest activity

Dec 2021